enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of “Buy” by Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned a consensus rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $30.38.

A number of equities research analysts have recently issued reports on the stock. Raymond James assumed coverage on shares of enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of enGene in a research report on Friday, December 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Finally, Citizens Jmp upgraded enGene to a “strong-buy” rating in a research note on Monday, November 18th.

Insiders Place Their Bets

In related news, major shareholder Growth Opportunities F. Forbion acquired 11,844 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was acquired at an average price of $6.55 per share, with a total value of $77,578.20. Following the purchase, the insider now directly owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. This trade represents a 0.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares in the company, valued at $57,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 420,965 shares of company stock worth $2,651,103 over the last three months. Insiders own 13.70% of the company’s stock.

Institutional Trading of enGene

Several institutional investors have recently modified their holdings of ENGN. Logos Global Management LP raised its stake in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after buying an additional 389,918 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after buying an additional 619,100 shares in the last quarter. SR One Capital Management LP bought a new position in shares of enGene during the second quarter valued at about $4,715,000. Finally, Wolverine Asset Management LLC purchased a new position in shares of enGene in the 3rd quarter worth approximately $37,000. Institutional investors own 64.16% of the company’s stock.

enGene Trading Down 12.1 %

Shares of NASDAQ:ENGN opened at $6.59 on Friday. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The business has a 50 day moving average of $8.23 and a 200-day moving average of $8.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, equities analysts predict that enGene will post -1.52 earnings per share for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.